AVDL - Avadel Pharmaceuticals plc
(NaN%)
Sell
Weak Growth●Stock Price Very High
25%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -62.28%
Operating Income turning Positive
Net Income turning Positive
Earnings Per Share (EPS) turning Positive
Net Margin is 31.47%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 17.44
Debt Ratio is 0.48
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.41
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Avadel Pharmaceuticals plc (AVDL) - https://www.avadel.com/
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Medicinal and Botanical Manufacturing
Sector - Manufacturing
CEO - Gregory Divis
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.